USPTO Examiner STOCKTON LAURA LYNNE - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18666109SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINEMay 2024March 2025Allow1000YesNo
18437502QUINOLINE COMPOUNDS AS INHIBITORS OF KRASFebruary 2024March 2025Allow1301NoNo
18436024OX2R CompoundsFebruary 2024April 2025Abandon1401NoNo
18434560Cyclic Thiol ProdrugsFebruary 2024May 2025Abandon1501NoNo
18422175INDOLOCARBAZOLE ANALOGS OF STAUROSPORINE AND METHODS OF SYNTHESIS THEREOFJanuary 2024August 2024Allow700YesNo
18422793PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOFJanuary 2024May 2025Abandon1610NoNo
18543691SYNTHETIC ROUTE TO 2,2',6,6'-TETRAISOPROPYL-4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTIONDecember 2023March 2024Allow300YesNo
18540206PHOTOSWITCHABLE ISOMERIZATION OF STERICALLY HINDERED 2,2',6,6'-TETRAISOPROPYL-4,4'-DIETHYNYLAZOBENZENEDecember 2023March 2024Allow300YesNo
18534171SYNTHETIC ROUTE TO 2,2'-DIMETHYL-4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTIONDecember 2023March 2024Allow300YesNo
18526983MODULATORS OF EUKARYOTIC INITIATION FACTOR 2December 2023April 2025Allow1711NoNo
18516091TROPOMYOSIN-RELATED KINASE (trk) INHIBITORSNovember 2023February 2025Allow1410YesNo
18388084PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATHNovember 2023December 2024Allow1320YesNo
183846854-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300YesNo
18383896Pyridinylcyanoguanidine Derivative and Use ThereofOctober 2023June 2024Allow800YesNo
18490942BENZOMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORSOctober 2023February 2025Allow1610YesNo
184889726-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300YesNo
18486487CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUNDOctober 2023October 2024Allow1210NoNo
183796094-METHOXY-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023December 2023Allow200YesNo
184832927-(4-((5-(2-BROMOBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDOctober 2023January 2024Allow310NoNo
18472101ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORSSeptember 2023March 2025Abandon1710NoNo
18465497DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORSSeptember 2023April 2025Allow1921YesNo
18354362ANTIVIRAL COMPOUNDSJuly 2023November 2024Allow1600NoNo
183502462-Methyl-QuinazolinesJuly 2023January 2025Abandon1801NoNo
18259578METHOD OF SYNTHESIZING INDOLE COMPOUNDSJune 2023March 2025Allow2021YesNo
18339506STING AGONISTIC COMPOUNDJune 2023August 2024Allow1410NoNo
18338096KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USEJune 2023December 2024Allow1810NoNo
18337329ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVESJune 2023February 2025Allow2020YesNo
18211134COMPOUNDS FOR TREATING HUNTINGTON'S DISEASEJune 2023December 2024Abandon1801NoNo
18335803INHIBITORS OF MEK KINASEJune 2023June 2024Allow1200YesNo
18202072METHODS AND FORMULATIONS FOR TREATMENT OF SPINOBULBAR MUSCULAR ATROPHYMay 2023December 2024Abandon1901NoNo
18322890LPA RECEPTOR ANTAGONISTS AND USES THEREOFMay 2023July 2024Allow1420NoNo
18144890Prodrugs of Fumarates and Their Use in Treating Various DiseasesMay 2023May 2024Allow1210NoNo
18142842CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASESMay 2023September 2024Allow1620NoNo
18307911METHODS OF PREPARING GLUFOSINATEApril 2023December 2024Allow1920YesNo
18303264AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORSApril 2023February 2025Abandon2201NoNo
18301179PHOSPHOLIPID COMPOUNDS AND USES THEREOFApril 2023February 2024Allow1021YesNo
18125961INHIBITORS OF THE WNT/BETA-CATENIN PATHWAYMarch 2023May 2025Allow2531NoNo
18179211TLR7/8 ANTAGONISTS AND USES THEREOFMarch 2023December 2024Abandon2111NoNo
18177408SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINEMarch 2023July 2024Allow1710YesNo
18175074INHIBITORS OF MEK KINASEFebruary 2023May 2023Allow300YesNo
18108785PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOFFebruary 2023May 2024Abandon1510NoNo
18166689ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOFFebruary 2023February 2024Allow1211YesNo
18099760PYRIDINIUM SALTS AND METHODS OF USEJanuary 2023August 2024Allow1911YesNo
18147178Cyclic Thiol ProdrugsDecember 2022November 2023Allow1111YesNo
18082847CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDSDecember 2022October 2023Allow1010NoNo
18080723Pyridinylcyanoguanidine Derivative and Use ThereofDecember 2022November 2023Allow1111NoNo
18074219Antiviral CompoundsDecember 2022February 2024Abandon1410NoNo
18074168DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONSDecember 2022April 2024Abandon1610NoNo
17988753SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINENovember 2022July 2024Abandon2020NoNo
17998355PYRIDINE DERIVATIVE AND APPLICATION THEREOFNovember 2022June 2025Allow3100YesNo
18050883IRAK4 DEGRADERS AND SYNTHESIS THEREOFOctober 2022August 2024Allow2111YesNo
17971547OX2R CompoundsOctober 2022September 2023Allow1121YesNo
17919483GPR52 MODULATORS AND METHODS OF USEOctober 2022May 2025Allow3100YesNo
18046303QUINOLINE COMPOUNDS AS INHIBITORS OF KRASOctober 2022December 2023Allow1401YesNo
18045647BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOFOctober 2022October 2024Allow2411NoNo
17938890RAS INHIBITORSOctober 2022August 2024Allow2211NoNo
17947593HEPATITIS B CAPSID ASSEMBLY MODULATORSSeptember 2022January 2024Abandon1621NoNo
17946587ANTIBACTERIAL COMPOUNDSSeptember 2022August 2023Allow1111YesNo
17894412ANTIVIRAL HETEROCYCLIC COMPOUNDSAugust 2022January 2024Allow1711YesNo
17798637METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUNDAugust 2022September 2024Allow2520YesNo
17883350TROPOMYOSIN-RELATED KINASE (trk) INHIBITORSAugust 2022July 2023Allow1110YesNo
17427778PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MIDDLE EAST RESPIRATORY SYNDROMEJuly 2022April 2025Allow4400YesNo
17795778COMPOUNDS AND USES THEREOFJuly 2022April 2025Allow3300YesNo
17815064METHOD FOR PRODUCING DIFLUOROMETHYL-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUNDJuly 2022June 2025Allow3401NoNo
17861740CARBON CAPTURE, STORAGE, AND RECYCLING COMPOSITIONSJuly 2022March 2024Allow2001YesNo
178622902-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOFJuly 2022December 2024Allow2920NoNo
17791852MULTI-AZIRIDINE COMPOUNDJuly 2022June 2025Allow3610YesNo
17856915SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUESJuly 2022April 2024Allow2211YesNo
17855336MK2 DEGRADERS AND USES THEREOFJune 2022June 2024Allow2321YesNo
17845469DIACYLGLYCEROL KINASE MODULATING COMPOUNDSJune 2022October 2023Allow1611YesNo
17787522CARBACYCLIC PHOSPHATIDIC ACID COMPOUNDJune 2022December 2023Allow1810NoNo
17786593PHOSPHATE DERIVATIVES OF RORGAMMA MODULATORS AND USES THEREOFJune 2022April 2025Allow3400YesNo
17786159AMINO DITHIOPERACID THIOESTER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOFJune 2022December 2024Allow3010NoNo
17835106BICYCLIC HETEROARYL DERIVATIVES AND PREPARATION AND USES THEREOFJune 2022December 2022Allow700NoNo
17826711P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOFMay 2022October 2023Allow1711YesNo
17826479PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAXMay 2022December 2024Abandon3121NoNo
17780052CANNABINOID DERIVATIVESMay 2022April 2025Allow3411YesNo
17755852NOVEL DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEMay 2022March 2025Allow3500YesNo
17719653COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASESApril 2022March 2024Allow2311YesNo
17765856CANNABINOID DERIVATIVESApril 2022August 2024Allow2821YesNo
17762771INDAZOLE CARBOXAMIDES AS KINASE INHIBITORSMarch 2022November 2024Allow3200YesNo
17699944SUBSTITUTED INDOLE COMPOUNDSMarch 2022April 2023Allow1201YesNo
17698283REDUCING AGENTS AND USES THEREOFMarch 2022April 2024Allow2421YesNo
17698289CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASESMarch 2022February 2023Allow1110NoNo
17698924Small Molecule Agonists and Antagonists of NR2F6 Activity in HumansMarch 2022October 2024Allow3140NoNo
177608302,5-DIMERCAPTO-1,3,4-THIADIAZOLE (DMTD) DERIVATIVESMarch 2022January 2025Allow3410YesNo
17688709ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4March 2022July 2023Allow1611YesNo
176790753,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAMEFebruary 2022May 2023Allow1511YesNo
17637365Nucleoside Prodrugs and Uses Related TheretoFebruary 2022October 2023Abandon1911YesNo
17636701PYRIDAZINE COMPOUND AND HERBICIDEFebruary 2022February 2025Allow3600YesNo
17634313Reduction of the odor of monothiocarbonate compounds by addition of oxidantsFebruary 2022December 2024Allow3410YesNo
17629186METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUNDJanuary 2022July 2023Allow1800YesNo
17628980COMPOUND, COMPOSITION, FILM, LAMINATE, AND DISPLAY DEVICEJanuary 2022November 2023Allow2211NoNo
17629167METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUNDJanuary 2022August 2024Allow3120NoNo
17628312COLOR MATERIAL COMPOUNDJanuary 2022November 2024Allow3400YesNo
17576410AMINOPYRIMIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORSJanuary 2022January 2024Allow2420YesNo
17576089FUSED IMIDAZO-PIPERIDINE JAK INHIBITORSJanuary 2022January 2023Allow1210NoNo
17626519CANNABINOID DERIVATIVESJanuary 2022February 2024Allow2511YesNo
17626518CANNABINOID DERIVATIVESJanuary 2022November 2024Allow3431YesNo
17570536KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USEJanuary 2022March 2023Allow1410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STOCKTON, LAURA LYNNE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
9
(75.0%)
Examiner Reversed
3
(25.0%)
Reversal Percentile
36.4%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
114
Allowed After Appeal Filing
36
(31.6%)
Not Allowed After Appeal Filing
78
(68.4%)
Filing Benefit Percentile
45.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 31.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner STOCKTON, LAURA LYNNE - Prosecution Strategy Guide

Executive Summary

Examiner STOCKTON, LAURA LYNNE works in Art Unit 1626 and has examined 2,061 patent applications in our dataset. With an allowance rate of 73.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.

Allowance Patterns

Examiner STOCKTON, LAURA LYNNE's allowance rate of 73.3% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by STOCKTON, LAURA LYNNE receive 1.46 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STOCKTON, LAURA LYNNE is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by STOCKTON, LAURA LYNNE. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.7% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 36.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 33% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.4% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 82.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 49.7% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 11.8% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.